IPSEY Quote, Financials, Valuation and Earnings

DBV Technologies SA has a net margin of -- compared to Ipsen SA's net margin of --. Ipsen SA's return on equity of -- beat DBV Technologies SA's return on equity of --.

Ipsen SA has a consensus price target of --, signalling downside risk potential of --. On the other hand DBV Technologies SA has an analysts' consensus of $22.63 which suggests that it could grow by 249.07%. Given that DBV Technologies SA has higher upside potential than Ipsen SA, analysts believe DBV Technologies SA is more attractive than Ipsen SA.

Ipsen SA has a beta of 0.803, which suggesting that the stock is 19.67% less volatile than S&P 500. In comparison DBV Technologies SA has a beta of -0.080, suggesting its less volatile than the S&P 500 by 108.034%.

Ipsen SA has a quarterly dividend of $0.33 per share corresponding to a yield of 1.15%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ipsen SA pays 28.79% of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend. Ipsen SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Ipsen SA quarterly revenues are --, which are smaller than DBV Technologies SA quarterly revenues of --. Ipsen SA's net income of -- is lower than DBV Technologies SA's net income of -$23M. Notably, Ipsen SA's price-to-earnings ratio is 12.43x while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ipsen SA is 2.66x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.

Genfit SA has a net margin of -- compared to Ipsen SA's net margin of --. Ipsen SA's return on equity of -- beat Genfit SA's return on equity of --.

Ipsen SA has a consensus price target of --, signalling downside risk potential of --. On the other hand Genfit SA has an analysts' consensus of $10.17 which suggests that it could grow by 198.81%. Given that Genfit SA has higher upside potential than Ipsen SA, analysts believe Genfit SA is more attractive than Ipsen SA.

Ipsen SA has a beta of 0.803, which suggesting that the stock is 19.67% less volatile than S&P 500. In comparison Genfit SA has a beta of 1.222, suggesting its more volatile than the S&P 500 by 22.243%.

Ipsen SA has a quarterly dividend of $0.33 per share corresponding to a yield of 1.15%. Genfit SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ipsen SA pays 28.79% of its earnings as a dividend. Genfit SA pays out -- of its earnings as a dividend. Ipsen SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Ipsen SA quarterly revenues are --, which are smaller than Genfit SA quarterly revenues of --. Ipsen SA's net income of -- is lower than Genfit SA's net income of --. Notably, Ipsen SA's price-to-earnings ratio is 12.43x while Genfit SA's PE ratio is 32.57x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ipsen SA is 2.66x versus 5.85x for Genfit SA. Usually stocks with elevated PS ratios are considered overvalued.

Innate Pharma SA has a net margin of -- compared to Ipsen SA's net margin of --. Ipsen SA's return on equity of -- beat Innate Pharma SA's return on equity of -72.79%.

Ipsen SA has a consensus price target of --, signalling downside risk potential of --. On the other hand Innate Pharma SA has an analysts' consensus of $8.02 which suggests that it could grow by 319.9%. Given that Innate Pharma SA has higher upside potential than Ipsen SA, analysts believe Innate Pharma SA is more attractive than Ipsen SA.

Ipsen SA has a beta of 0.803, which suggesting that the stock is 19.67% less volatile than S&P 500. In comparison Innate Pharma SA has a beta of 0.334, suggesting its less volatile than the S&P 500 by 66.567%.

Ipsen SA has a quarterly dividend of $0.33 per share corresponding to a yield of 1.15%. Innate Pharma SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ipsen SA pays 28.79% of its earnings as a dividend. Innate Pharma SA pays out -- of its earnings as a dividend. Ipsen SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Ipsen SA quarterly revenues are --, which are smaller than Innate Pharma SA quarterly revenues of --. Ipsen SA's net income of -- is lower than Innate Pharma SA's net income of --. Notably, Ipsen SA's price-to-earnings ratio is 12.43x while Innate Pharma SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ipsen SA is 2.66x versus 11.42x for Innate Pharma SA. Usually stocks with elevated PS ratios are considered overvalued.

Inventiva SA has a net margin of -- compared to Ipsen SA's net margin of --. Ipsen SA's return on equity of -- beat Inventiva SA's return on equity of --.

Ipsen SA has a consensus price target of --, signalling downside risk potential of --. On the other hand Inventiva SA has an analysts' consensus of $11.51 which suggests that it could grow by 291.49%. Given that Inventiva SA has higher upside potential than Ipsen SA, analysts believe Inventiva SA is more attractive than Ipsen SA.

Ipsen SA has a beta of 0.803, which suggesting that the stock is 19.67% less volatile than S&P 500. In comparison Inventiva SA has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Ipsen SA has a quarterly dividend of $0.33 per share corresponding to a yield of 1.15%. Inventiva SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ipsen SA pays 28.79% of its earnings as a dividend. Inventiva SA pays out -- of its earnings as a dividend. Ipsen SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Ipsen SA quarterly revenues are --, which are smaller than Inventiva SA quarterly revenues of --. Ipsen SA's net income of -- is lower than Inventiva SA's net income of --. Notably, Ipsen SA's price-to-earnings ratio is 12.43x while Inventiva SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ipsen SA is 2.66x versus 308.88x for Inventiva SA. Usually stocks with elevated PS ratios are considered overvalued.